174 related articles for article (PubMed ID: 1488999)
1. Long-term suppression of secondary hyperparathyroidism by intravenous 1 alpha-hydroxyvitamin D3 in patients on chronic hemodialysis.
Brandi L; Daugaard H; Tvedegaard E; Nielsen PK; Egsmose C; Storm T; Olgaard K
Am J Nephrol; 1992; 12(5):311-8. PubMed ID: 1488999
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. Effect of intravenous 1-alpha-hydroxyvitamin D3 on secondary hyperparathyroidism in chronic uremic patients on maintenance hemodialysis.
Brandi L; Daugaard H; Tvedegaard E; Storm T; Olgaard K
Nephron; 1989; 53(3):194-200. PubMed ID: 2797340
[TBL] [Abstract][Full Text] [Related]
4. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis.
Brandi L; Daugaard H; Nielsen PK; Jensen LT; Egsmose C; Olgaard K
Nephron; 1996; 74(1):89-103. PubMed ID: 8883025
[TBL] [Abstract][Full Text] [Related]
5. Intermittent intravenous followed by intermittent oral 1 alpha(OH)D3 treatment of secondary hyperparathyroidism in uraemia.
Brandi L; Daugaard H; Egsmose C; Tvedegaard E; Kjaerulff Nielsen P; Olgaard K
J Intern Med; 1996 Apr; 239(4):353-60. PubMed ID: 8774390
[TBL] [Abstract][Full Text] [Related]
6. Prevention of hyperparathyroidism in patients on maintenance dialysis by intravenous 1-alpha-hydroxyvitamin D3 in association with Mg(OH)2 as sole phosphate binder. A randomized comparative study with the association CaCO3 +/- Mg(OH)2.
Mornière P; Maurouard C; Boudailliez B; Westeel PF; Achard JM; Boitte F; el Esper N; Compagnon M; Maurel G; Bouillon R
Nephron; 1992; 60(2):154-63. PubMed ID: 1552999
[TBL] [Abstract][Full Text] [Related]
7. [Long-term treatment with large doses of alphacalicidol in secondary hyperparathyroidism of patients dialyzed for end stage renal failure].
Matuszkiewicz-Rowińska J; Niemczyk S; Pacocha E; Puka J; Switalski M; Bogdańska-Straszyńska B; Ostrowski K
Pol Arch Med Wewn; 1996 Jul; 96(1):15-22. PubMed ID: 8966141
[TBL] [Abstract][Full Text] [Related]
8. [Effect of pulse therapy using 1 alpha(OH)D on secondary hyperparathyroidism in patients on maintenance hemodialysis].
Yoshida K; Hirayama A; Tanaka N; Yasukawa M; Saka M; Kaneko Y; Maruyama Y; Motomiya Y; Ozono S; Hirao Y
Nihon Jinzo Gakkai Shi; 1990 Oct; 32(10):1117-23. PubMed ID: 2287104
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of secondary hyperparathyroidism in hemodialysis patients with oral pulse 1-alpha-hydroxy-cholecalciferol therapy.
Rapoport J; Mostoslavski M; Ben-David A; Knecht A; Blau A; Arad J; Zlotnik M; Chaimovitz C
Nephron; 1996; 72(2):150-4. PubMed ID: 8684518
[TBL] [Abstract][Full Text] [Related]
10. Comparison between 1alpha(OH)D3 and 1,25(OH)2D3 on the suppression of plasma PTH levels in uremic patients, evaluated by the 'whole' and 'intact' PTH assays.
Brandi L; Egfjord M; Olgaard K
Nephron Clin Pract; 2005; 99(4):c128-37. PubMed ID: 15722644
[TBL] [Abstract][Full Text] [Related]
11. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.
Slatopolsky E; Weerts C; Thielan J; Horst R; Harter H; Martin KJ
J Clin Invest; 1984 Dec; 74(6):2136-43. PubMed ID: 6549016
[TBL] [Abstract][Full Text] [Related]
12. Long-term effects of intermittent oral alphacalcidol, calcium carbonate and low-calcium dialysis (1.25 mmol L-1) on secondary hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis.
Brandi L; Nielsen PK; Bro S; Daugaard H; Olgaard K
J Intern Med; 1998 Aug; 244(2):121-31. PubMed ID: 10095798
[TBL] [Abstract][Full Text] [Related]
13. Conversion of oral alfacalcidol to oral calcitriol in the treatment of secondary hyperparathyroidism in chronic hemodialysis patients.
Rauscher S; Lafrance JP; Pichette V; Bell RZ; Desforges K; Lepage L; Ouellet G; Ouimet D; Leblanc M; Lamarche C; Bezzaoucha S; Vallee M
Int Urol Nephrol; 2017 Feb; 49(2):325-328. PubMed ID: 27822674
[TBL] [Abstract][Full Text] [Related]
14. Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism.
Akiba T; Marumo F; Owada A; Kurihara S; Inoue A; Chida Y; Ando R; Shinoda T; Ishida Y; Ohashi Y
Am J Kidney Dis; 1998 Aug; 32(2):238-46. PubMed ID: 9708607
[TBL] [Abstract][Full Text] [Related]
15. Effective suppression of parathyroid hormone by 1 alpha-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism.
Tan AU; Levine BS; Mazess RB; Kyllo DM; Bishop CW; Knutson JC; Kleinman KS; Coburn JW
Kidney Int; 1997 Jan; 51(1):317-23. PubMed ID: 8995749
[TBL] [Abstract][Full Text] [Related]
16. Alphacalcidol oral pulses are effective in secondary hyperparathyroidism prior to dialysis.
Koskimies O; Ala-Houhala M
Clin Nephrol; 1996 Jul; 46(1):70-1. PubMed ID: 8832157
[TBL] [Abstract][Full Text] [Related]
17. 1-alpha-Hydroxyvitamin D3 derivatives in the treatment of renal bone diseases: justification and optimal modalities of administration.
Fournier A; Morinière PH; Oprisiu R; Yverneau-Hardy P; Westeel PF; Mazouz H; el Esper N; Ghazali A; Boudailliez B
Nephron; 1995; 71(3):254-83. PubMed ID: 8569975
[TBL] [Abstract][Full Text] [Related]
18. Acute effect of dialysate calcium concentration and intravenous vitamin D3 on the secretion of parathyroid hormone in hemodialysis patients.
Saha H; Pietilä K; Mustonen J; Pasternack A; Mörsky P
Clin Nephrol; 1992 Sep; 38(3):145-8. PubMed ID: 1395167
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial of intermittent versus continuous oral alfacalcidol treatment of hyperparathyroidism in end-stage renal disease.
Tarrass F; Yazidi A; Sif H; Zamd M; Benghanem MG; Ramdani B
Clin Nephrol; 2006 Jun; 65(6):415-8. PubMed ID: 16792136
[TBL] [Abstract][Full Text] [Related]
20. Effects on serum parathyroid hormone of intravenous treatment with alphacalcidol in patients on chronic hemodialysis.
Ljunghall S; Althoff P; Fellström B; Marjanovic B; Nisell J; Weiss L; Wide L
Nephron; 1990; 55(4):380-5. PubMed ID: 2392190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]